European Commission proposes a change to intellectual property rules to let generic drugmakers enter non-EU markets faster. Patent holders are not happy
The era of prescription digital health has dawned with approval of an app assessed to the same standard of clinical evidence as a conventional drug. Now pharma companies and digital therapy pioneers are forging development and marketing deals, while EU regulators and payers flounder
Automated surveillance was 100% accurate, while experts relying on manual recording and interpretation of individual patient data made errors. The automated system is faster and can be programmed to run checks at any timea
Using anonymised information from electronic health records is an efficient and low-cost way of following up subjects years after the treatment phase of a study completes
IMI is celebrating its 10th anniversary with a high-level event in Brussels on 27 June. Join us to meet IMI projects and explore their successes and the impact they are having on drug development.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.